Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB

References

• WHO. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO Progress Report. 2011. Geneva: World Health Organization.
   Google Scholar
• World Health Organization. Global tuberculosis report 2018. World Health Organization; 2018.
   Google Scholar
• Calligaro GL, Moodley L, Symons G, et al. The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis. 2014;6(3):186–195.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (U.S.) N, National Center for Infectious Diseases (U.S.) N, Shah N, et al. Emerging infectious diseases. 387. Centers for Disease Control and Prevention (CDC); 1995
   Google Scholar
• S. An integration of interdisciplinary translational research in anti-TB drug discovery: out of the university research laboratories to combat Mycobacterium tuberculosis. Mol Biol. 2013;2(2):e1081–3).
   Google Scholar
• Nasiruddin M, Neyaz MK, Das S. Nanotechnology-based approach in tuberculosis treatment. Res Treat. 2017;2017:1–12.
   Google Scholar
• Tiberi S, Buchanan R, Caminero JA, et al. The challenge of the new tuberculosis drugs. 2017 Mar 1;462e41–51.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019.
   Google Scholar
• World Health Organization. WHO treatment guidelines for -and -resistant tuberculosis Pre-final text. 2018
   Google Scholar
• Riley LW. Drug-resistant tuberculosis. Clin Infect Dis An Off Publ Infect Dis Soc Am. 1993;17 Suppl 2S442–S446.
   PubMed Web of Science ®Google Scholar
• Gygli SM, Borrell S, Trauner A, et al. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354–373.
   PubMed Web of Science ®Google Scholar
• Alderwick LJ, Harrison J, Lloyd GS, et al. The mycobacterial cell wall– and Cold Spring Harb Perspect 2015 Mar 27;58a021113.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Chinnapapagari S, Thompson CJ. - of trehalose dimycolate for the intrinsic resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis. J Bacteriol. 2005 Oct 1;18719)6603–6611.
   PubMed Web of Science ®Google Scholar
• Warrier T, Martinez-Hoyos M, Marin-Amieva M, et al. Identification of novel anti- compounds by screening a pharmaceutical small-molecule library against Mycobacterium tuberculosis. ACS Infect Dis. 2015 Dec 11;112)580–585.
   PubMed Web of Science ®Google Scholar
• Zaunbrecher MA, Sikes RD, Metchock B, et al. chromosomally encoded aminoglycoside acetyltransferase resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2009 Nov1064720004–20009.
   PubMed Web of Science ®Google Scholar
• Wang F, Cassidy C, Sacchettini JC. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother. 2006 Aug 1;508)2762–2771.
   PubMed Web of Science ®Google Scholar
• Ferber D mimics DNA helps tuberculosis bacteria resist antibiotics. 2005
   Google Scholar
• Madsen CT, Jakobsen L, Buriánková K, et al. Erm37) slips on to confer atypical resistance in Mycobacterium tuberculosis. J Biol Chem. 2005 Nov 25;28047)38942–38947.
   PubMed Web of Science ®Google Scholar
• Nasiri MJ, Haeili M, Ghazi M, et al. New insights the intrinsic and acquired drug resistance mechanisms in Front Microbiol. 2017 Apr 25;8:681.
   PubMed Web of Science ®Google Scholar
• Silva PEA, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417–1430.
   PubMed Web of Science ®Google Scholar
• Pipeline | Working Group for New TB Drugs. https://www.newtbdrugs.org/pipeline/clinical.
   Google Scholar
• Yadav S, Rawal G, Baxi M. : a novel agent for the treatment of multidrug-resistant tuberculosis. J Clin Diagn Res. 2016 Aug108FM01–FM02.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of in the treatment of multidrug-resistant tuberculosis: interim policy guidance. World Health Organization; 2014.
   Google Scholar
• World Health Organization. Global tuberculosis report. World Health Organization; 2018.
   Google Scholar
• Search Delamanid (NCT00685360) - List Results - go. https://clinicaltrials.gov
   Google Scholar
• Skripconoka V, Danilovits M, Pehme L, et al. outcomes and reduces mortality in multidrug-resistant tuberculosis. Respir J. 2013 Jun4161393–1400.
   PubMed Web of Science ®Google Scholar
• Xavier AS, Lakshmanan M. : a new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul53222–224.
   PubMedGoogle Scholar
• Mahajan R. : first FDA-approved tuberculosis drug in 40 years. J Appl Basic Res. 2013 Jan311–2.
   PubMedGoogle Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005 Jan 14;3075707)223–227.
   PubMed Web of Science ®Google Scholar
• Search Bedaquiline (NCT00449644) - List Results https://clinicaltrials.gov
   Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012 Jun 1;566)3271–3276.
   PubMed Web of Science ®Google Scholar
• Field SK. the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Chronic Dis. 2015 Jul64170–184.
   Google Scholar
• Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of (PA-824), and during the first 8 weeks of treatment: a phase 2b, open-label, partly trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 2;3859979)1738–1747.
   PubMed Web of Science ®Google Scholar
• Search NCT01215851 - List Results https://clinicaltrials.gov
   Google Scholar
• Search NCT01498419 - List Results https://clinicaltrials.gov
   Google Scholar
• Wallis RS, Dawson R, Friedrich SO, et al. of (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014 Apr 14;94e94462.
   PubMed Web of Science ®Google Scholar
• Search NCT01225640 - List Results https://clinicaltrials.gov
   Google Scholar
• Heinrich N, Dawson R, Du Bois J, et al. Early phase evaluation of SQ109 alone and in combination TB patients. J Antimicrob Chemother. 2015 May7051558–1566.
   PubMed Web of Science ®Google Scholar
• Search NCT01218217 - List Results https://clinicaltrials.gov
   Google Scholar
• Neres J, Pojer F, Molteni E, et al. Structural basis for -mediated killing of Mycobacterium tuberculosis. 2012 Sep 5;4150)150ra121–150ra121.
   Google Scholar
• RC, Uplekar S, Cole ST. Cross-Resistance between and through of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014 May 1;585)2979–2981.
   PubMed Web of Science ®Google Scholar
• Sarasija S, Patil J. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012 Jan29144.
   PubMedGoogle Scholar
• Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001 Jun476829–835.
   PubMed Web of Science ®Google Scholar
• Johnson CM, Pandey R, Sharma S, et al. Oral therapy using nanoparticle-encapsulated drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Oct 1;4910)4335–4338.
   PubMed Web of Science ®Google Scholar
• Parikh R, Dalwadi S, Aboti P, et al. Inhaled of antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of J Antibiot (Tokyo). 2014 May675387–394.
   PubMed Web of Science ®Google Scholar
• Bibhas CM, Gitanjali M, Subas CD, et al. Exploring the use of lipid based nano-formulations for the management of tuberculosis. J Nanosci Curr Res. 2017;2(112):2572–2813.
   Google Scholar
• Garcia Contreras L, Sung J, Ibrahim M, et al. Pharmacokinetics of inhaled porous particles for tuberculosis treatment: insight into absorption from the lungs of guinea pigs. 2015 Aug1282642–2650.
   Google Scholar
• Smaldone G, Berkland C, Gonda I, et al. Ask the Experts: the benefits and challenges of pulmonary drug delivery. 2013 Aug48905–913.
   Google Scholar
• Thulasiramaraju TV, Kumar BT, Nikilesh Babu M. Pulmonary drug delivery system: an overview. Asian J Res Pharm Sci Biotechnol. 2013;16–34.
   Google Scholar
• Amarnath Praphakar R, Munusamy MA, Sadasivuni KK, et al. Targeted delivery of to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance -loaded polyester amides Int J Pharm. 2016 Nov5131–2)628–635.
   PubMedGoogle Scholar
• Ahmad MI, Ungphaiboon S, Srichana T. The development of dimple-shaped carrier for dry powder inhaler. Drug Dev Pharm. 2015 May415791–800.
   PubMed Web of Science ®Google Scholar
• Debnath SK, Srinivasan S, Debnath M. Development of dry powder inhaler containing -PLGA nanoparticles optimized through statistical design: study. Open Nanomed J. 2017 Nov4130–40.
   Google Scholar
• Wang C, Hickey AJ. for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech. 2010 Jun112538–549.
   PubMed Web of Science ®Google Scholar
• Gaur PK, Mishra S, Gupta VB, et al. Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized and in situ formed aerosolized Drug Dev Pharm. 2010 Jun366638–646.
   PubMed Web of Science ®Google Scholar
• Patil-Gadhe AA, Kyadarkunte AY, Pereira M, et al. - inhalation: in vitro and in vivo toxicity. Toxicol Int. 2014;21(3):275–282.
   PubMedGoogle Scholar
• Singh C, Koduri LVSK, Dhawale V, et al. Potential of aerosolized for modulation of pulmonary pharmacokinetics and bio-distribution. Int J Pharm. 2015 Nov4952627–632.
   PubMedGoogle Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled systems for pulmonary delivery. Res. 2009 Aug2681847–1855.
   Google Scholar
• Pastor M, Salomon CJ, Esquisabel A, et al. Pulmonary drug delivery: a review on for antibacterial chemotherapy. J Antimicrob Chemother. 2015 July702945–2955.
   PubMed Web of Science ®Google Scholar
• Loretz B, Bernkop-Schnürch A. In vitro cytotoxicity testing of non- and for oral gene delivery. 2007 June 10;12)139–148.
   Google Scholar
• Zolfagharnia B, Mortazavian E, Kaviani D, et al. Preparation and evaluation of composed of methylated as a new strategy for drug delivery of insulin. J. 2017;4(2):83–88.
   Google Scholar
• Shah ND, V V S, Chivate ND. Pulmonary drug delivery: a promising approach. J Appl Pharm 2012;26)33–37.
   Google Scholar
• Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012 Jan29144–49.
   PubMedGoogle Scholar
• Moreno-Sastre M, Pastor M, Salomon CJ, et al. Pulmonary drug delivery: a review on for antibacterial chemotherapy. J Antimicrob Chemother. 2015 Nov 1;7011)2945–2955.
   PubMed Web of Science ®Google Scholar
• Liang Z, Ni R, Zhou J, et al. Recent advances in controlled pulmonary drug delivery. Drug Discov Today. 2015 Mar 1;203)380–389.
   PubMed Web of Science ®Google Scholar
• Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002;19(4–5):425–498.
   PubMed Web of Science ®Google Scholar
• Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004 Dec 1;14)315–320.
   PubMedGoogle Scholar
• Ozer AY. Alternative applications for drug delivery: nasal and pulmonary routes. Nanosystems for Biomedical Applications. 2007 (pp. 99-112). Dordrecht: Springer.
   Google Scholar
• Scheuch G, Kohlhaeufl MJ, Brand P, et al. Clinical perspectives on pulmonary systemic and delivery. Adv Drug Deliv Rev. 2006 Oct 31;589–10)996–1008.
   PubMed Web of Science ®Google Scholar
• Smyth HDC, Hickey AJ Controlled Pulmonary Drug Delivery. 2011
   Google Scholar
• Patton JS. The Lungs as a Portal of Entry for Systemic Drug Delivery. Proc Am Thorac Soc. 2004 Dec 1;14)338–344.
   PubMedGoogle Scholar
• Byron PR. Drug delivery devices: issues in drug development. Proc Am Thorac Soc. 2004 Dec 1;14)321–328.
   PubMedGoogle Scholar
• Sankhala S, Singh HS, Singh SK, et al. Factors that affect the lung deposition. Int J Mod Phys Conf Ser. 2013;22:729–732.
   Google Scholar
• Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Devices Evidence Res. 2015;8:131–139.
   Web of Science ®Google Scholar
• Hanif SNM, Garcia-Contreras L, Roy CJ, et al. Pharmaceutical aerosols for the treatment and prevention of Tuberculosis. Front Cell Infect Microbiol. 2012 Sep 7;2:118.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Malapit M, Mallory E, et al. for respiratory delivery. Nanotechnology, Biol 2015 Jul1151189–1199.
   PubMed Web of Science ®Google Scholar
• Costa A, Pinheiro M, Magalhães J, et al. The formulation of for treating tuberculosis. Adv Drug Deliv Rev. 2016;102:102–115.
   PubMed Web of Science ®Google Scholar
• Patil TS, Deshpande AS, Deshpande S, et al. Targeting pulmonary tuberculosis using -based dry powder inhalation: current status and futuristic need. J Drug Target. 2019 Jan 2;271)12–27.
   PubMed Web of Science ®Google Scholar
• De Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017 Apr 3;144)499–512.
   PubMed Web of Science ®Google Scholar
• Mehta P, Bothiraja C, Kadam S, et al. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future. Cells Nanomed Biotechnol. 2018 Oct 11;46:1–16
   Web of Science ®Google Scholar
• Lipp MM, Sung JC, inventors; Pulmatrix Inc, assignee. Monovalent metal cation powders for inhalation. United States patent application US 14/666,959. 2015 Aug 20.
   Google Scholar
• JK Welfare & Pharmascope Foundation. Dry powder inhalers-an overview. Int Res Pharm Sci. JK Welfare & Pharmascope Foundation.
   Google Scholar
• Shegokar R, Al Shaal L, Mitri K. Present status of research for treatment of tuberculosis. J Pharm Pharm Sci. 2011;14(1):100–116.
   PubMed Web of Science ®Google Scholar
• Smith JP. of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med. 2011 Dec844361–369.
   PubMedGoogle Scholar
• Sosnik A, Carcaboso ÁM, Glisoni RJ, et al. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2010 Mar 18;624–5)547–559.
   PubMed Web of Science ®Google Scholar
• Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998 Apr6641277–1281.
   PubMed Web of Science ®Google Scholar
• Debnath SK, Saisivam S, Debanth M, et al. Development and evaluation of Chitosan based dry powder inhalation formulations of Prothionamide. 2018 Jan 25;131e0190976
   Google Scholar
• Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) -based sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003 Nov526981–986.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005 Jul854227–234.
   PubMed Web of Science ®Google Scholar
• Patil JS, Devi VK, Devi K, et al. A novel approach for lung delivery -loaded in dry powder form for the treatment of tuberculosis. Lung India. 2015;32(4):331–338.
   PubMed Web of Science ®Google Scholar
• Ghalati PF, Keshavarzian E, Abouali O, et al. Numerical analysis of micro-and nano-particle deposition in a realistic human upper airway. Comput Biol 2012 Jan 1;421)39–49.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kleinstreuer C, Kim CS. Comparison of analytical and CFD models with regard to micron particle deposition in a human 16-generation airway model. Aerosol Sci. 2009;40:16–28.
   Web of Science ®Google Scholar
• Kolanjiyil AV, Kleinstreuer C. Computational analysis of aerosol-dynamics in a human whole-lung airway model. J Aerosol Sci. 2017 Dec 1;114:301–316.
   Web of Science ®Google Scholar
• Schneider CS, Xu Q, Boylan NJ, et al. do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. 2017 Apr 1;34e1601556.
   Google Scholar
• Garbuzenko OB, Mainelis G, Taratula O, et al. Inhalation treatment of lung cancer: the influence of composition, size and shape of on their lung accumulation and retention. Cancer Biol 2014 Mar11144.
   Google Scholar
• Costa-Gouveia J, Pancani E, Jouny S, et al. Combination therapy for tuberculosis treatment: pulmonary administration of and booster co-loaded Rep. 2017 Dec715390.
   Google Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KLMC, et al. Pulmonary delivery of -DNA enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine. 2004 Apr2213–14)1609–1615.
   PubMed Web of Science ®Google Scholar
• Ballester M, Nembrini C, Dhar N, et al. and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011 Sep29406959–6966.
   PubMed Web of Science ®Google Scholar
• Muttil P, Kaur J, Kumar K, et al. of anti-tuberculosis drugs. Eur J Pharm Sci. 2007 Oct322140–150.
   PubMed Web of Science ®Google Scholar
• G, Banerjee R. Evaluation of drug-loaded surfactants as drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res Part A. 2009 May;89A2281–292.
   Web of Science ®Google Scholar
• Greco E, Quintiliani G, Santucci MB, et al. Janus-faced enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. Proc Natl Acad Sci. 2012;109(21).
   PubMed Web of Science ®Google Scholar
• Gaspar DP, Gaspar MM, Eleutério CV, et al. lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery. 2017 Sep1492977–2990.
   Google Scholar
• Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug5182830–2836.
   PubMed Web of Science ®Google Scholar